Metabolic Adaptation in Acute Ischemic Events: The Critical Role of Acyl‐Coenzyme A Synthetase Family in Myocardial Infarction and Ischemic Stroke Authors: Yongfang Zhou, Fang Huang, Tao Yuan, Zhenyu Zhang, Srinivas Tipparaju, Celeste Yin‐Chieh Wu, Reggie Hui‐Chao Lee Published: 2026 ABSTRACT AbstractAcute ischemic events, such as myocardial infarction and ischemic stroke, are significant contributors to global morbidity and mortality. These pathological conditions, characterized by abrupt interruption of blood flow to critical tissues, induce substantial metabolic changes within affected tissues to maintain cellular viability under conditions of energy deprivation. ACSLs (acyl‐coenzyme A synthetase long‐chain family members) are key regulators of this metabolic adaptation, as they catalyze the conversion of long‐chain fatty acids into acyl‐coenzyme A thioesters, thereby affecting lipid metabolism, energy production, and cellular signaling pathways. Growing evidence highlights the crucial role of ACSLs in the pathophysiology of ischemic events because of their tightly regulated cell‐ and tissue‐specific responses to hypoxia, oxidative stress, and inflammation. In this review article, we explore the current literature on the molecular mechanisms by which ACSLs influence metabolic pathways, energy homeostasis, and cell fate determination during ischemia. Additionally, we evaluate whether ACSLs are promising therapeutic targets for reducing ischemic injury and promoting neuronal recovery. By understanding the complex interactions between ACSL activity and ischemic pathophysiology, this review article aims to identify ACSL research gaps, highlight new research directions, and explore novel therapeutic interventions for cardiovascular and neurological disorders.Keywords: acyl‐CoA synthetases long‐chain, cerebral ischemia, ischemia–reperfusion injury, ischemic stroke, lipid metabolism, myocardial infarctionSubject Categories: Myocardial Infarction, Cerebrovascular Disease/Stroke Nonstandard Abbreviations and Acronyms acyl‐coenzyme A synthetase long‐chain family members docosahexaenoic acid fatty acid oxidation ischemia–reperfusion injury ischemic stroke long‐chain fatty acids neutrophil extracellular traps Myocardial infarction (MI) and ischemic stroke (IS) are both significant contributors to morbidity and mortality worldwide, posing major public health challenges. 1 According to the American Heart Association's 2024 statistics, MI affects >7.5 million people annually worldwide, contributing to ∼15% of all deaths globally. In the United States specifically, there are 805 000 new MI cases each year, with coronary artery disease remaining as the leading cause of death. In contrast, stroke accounts for about 11% of total global mortality, and it represents 5% of all deaths (∼150 000 deaths annually) in the United States. 2 The economic burden of MI and IS in the United States is substantial, with combined costs exceeding $432 billion annually. 2 These high incidence and mortality rates highlight the urgent need for enhanced prevention strategies, early diagnosis, and targeted therapies to mitigate the extensive societal and economic impact. MI and IS are both characterized by disrupted cellular metabolism, particularly fatty acid (FA) metabolism, which serves as the primary source of energy for the heart and brain. 3 , 4 This is based on the fact that >70% of the heart's energy is derived from FA oxidation (FAO) in both humans and animal models under normal conditions. 5 Although the brain primarily relies on glucose metabolism, it also uses FA metabolism during metabolic stress conditions, such as ischemia, hypoxia, or energy crises when glucose supply becomes insufficient. 6 During and after MI, reduced oxygen availability in the cardiomyocytes diminishes FAO, leading to a compensatory shift to glycolysis to sustain energy production. 4 Although this metabolic reprogramming is initially protective, excessive high‐energy phosphate production from glycolysis can further exacerbate myocardial ischemia and dysfunction. 7 Similarly, following IS, the ischemic brain undergoes metabolic shifts in response to impaired oxygen delivery. Reduced oxidative phosphorylation can force neurons to rely on anaerobic glycolysis, resulting in lactate accumulation, cellular acidosis, and neuronal damage. 3 , 8 ACSLs (acyl‐coenzyme A [CoA] synthetase long‐chain family members) are a family of CoA synthetases that activate FAs with chain lengths of 12 to 20 carbon atoms by converting them into acyl‐CoA and acyl‐AMP derivatives. Five ACSL members have been identified in mammals, including ACSL1, ACSL3, ACSL4, ACSL5, and ACSL6. Each ACSL exhibits a unique tissue‐specific expression profile and metabolic functions. 9 For instance, ACSL1 is highly expressed in the heart, contributing to >90% of the total ACSL activity in murine cardiac tissue. 10 In contrast, ACSL4 and ACSL6 are highly expressed in neural tissues, where they play essential roles in brain lipid metabolism in humans, pigs, and mice. 11 , 12 ACSL4 primarily activates polyunsaturated FAs, such as arachidonic acid, and has been implicated in regulating inflammatory signaling pathways and oxidative stress responses. 13 Two central mechanisms are involved in the pathogenesis of MI and IS. By contrast, ACSL6 is predominantly expressed in the brain, where it supports neuronal membrane integrity through facilitating lipid synthesis and FA utilization, particularly during metabolic stress such as ischemia. 11 , 12 Compared with ACSL1, ACSL4, and ACSL6, both ACSL3 and ACSL5 exhibit relatively low expression in the adult brain and heart. ACSL3 displays transient upregulation during neuronal development, whereas ACSL5 is primarily expressed in the intestine and only modestly detectable in the brain and heart. 14 , 15 In addition, Table 1 summarizes the tissue distribution and distinct physiological versus pathological ischemia‐associated roles of ACSL isoforms across peripheral metabolic organs, the heart, and brain. In this review article, we summarize: The role of ACSL1 in MI (Figure 1) The role of ACSL1 in MI (Figure 1) The molecular mechanisms of ACSL4 and ACSL6 in IS‐induced brain injury (Figure 2) The molecular mechanisms of ACSL4 and ACSL6 in IS‐induced brain injury (Figure 2) The potential involvement of ACSLs in mediating brain–heart crosstalk under ischemic conditions (Figure 3) The potential involvement of ACSLs in mediating brain–heart crosstalk under ischemic conditions (Figure 3) Table 1Tissue Distribution and Context‐Dependent Roles of ACSL Isoforms in MI and ISIsoformPeripheral metabolic tissues (liver, adipose, skeletal muscle)HeartBrainPhysiological rolesPathological roles during MI/ISACSL1High expression in liver, adipose tissue, and skeletal musclePredominant cardiac isoform; major source of acyl‐coenzyme A for β‐oxidationExpressed in microglia, particularly under activated or neuroinflammatory states (e.g., Alzheimer's disease, Parkinson's disease)Fatty acid activation for β‐oxidation; regulation of lipid storage and metabolic substrate selectionUpregulation drives triglyceride accumulation, lipotoxicity, hypertrophy; promotes monocyte/macrophage neutrophil extracellular trap formation and thromboinflammation; contributes to neuroinflammationACSL3Abundant in skeletal muscle; present in liver and adipose tissueModest expressionHigh expression; enriched in astrocytes and subsets of neuronsMembrane phospholipid remodeling; support of neurodevelopmentLimited evidence; may modulate glioma metabolism and systemic metabolic dysregulation influencing cardiovascular riskACSL4High expression in liverModest expressionHigh expression, especially in hippocampus and cortex; enriched in neuronal and glial cellsPolyunsaturated fatty acid activation; regulation of lipid peroxidation and ferroptosis; synaptic maturationCentral driver of ferroptosis in ischemic stroke and cardiac ischemia–reperfusion injury; increases lipid peroxidation, mitochondrial dysfunction, and impaired mitophagyACSL5High expression in liver and adipose tissue; present in skeletal muscleModest expressionLow to moderate expressionFatty acid activation for β‐oxidation; regulation of systemic energy homeostasisElevated expression aggravates metabolic syndrome, obesity, and increased ischemic vulnerability; elevated in gliomas with increased cardiovascular riskACSL6Low expressionLow expressionMost brain‐enriched ACSL isoform, especially in cerebellum and hippocampus; enriched in neuronal and glial cellsDHA activation; maintenance of neuronal membrane composition; synaptic maturation; synthesis of proresolving lipid mediatorsDeficiency exacerbates IS injury via impaired DHA retention, reduced neuroprotectin D1/resolvins, and increased oxidative stressThis table summarizes the relative expression patterns of ACSL isoforms across peripheral metabolic tissues, heart, and brain, together with their major physiological functions and pathological contributions under ischemic conditions. Distinct ACSL isoforms exhibit tissue‐specific roles in fatty acid activation, lipid remodeling, and energy metabolism, while their dysregulation contributes to lipotoxicity, ferroptosis, neuroinflammation, and thromboinflammatory responses that link myocardial infarction and ischemic stroke. ACSL indicates acyl‐coenzyme A synthetase long‐chain family member; and DHA, docosahexaenoic acid. Tissue Distribution and Context‐Dependent Roles of ACSL Isoforms in MI and IS This table summarizes the relative expression patterns of ACSL isoforms across peripheral metabolic tissues, heart, and brain, together with their major physiological functions and pathological contributions under ischemic conditions. Distinct ACSL isoforms exhibit tissue‐specific roles in fatty acid activation, lipid remodeling, and energy metabolism, while their dysregulation contributes to lipotoxicity, ferroptosis, neuroinflammation, and thromboinflammatory responses that link myocardial infarction and ischemic stroke. ACSL indicates acyl‐coenzyme A synthetase long‐chain family member; and DHA, docosahexaenoic acid. Schematic illustration of ACSL1 functions in cardiomyocytes following MI. Following MI, cardiomyocytes experience an imbalance between lipid and glucose metabolism. ACSL1 catalyzes the conversion of LCFAs into LCFA‐CoAs, a critical step for ATP production and maintaining metabolic homeostasis. ACSL1 expression is upregulated post‐MI, leading to triglyceride accumulation, mitochondrial dysfunction, and increased ROS, which collectively impair fatty acid oxidation. IRI‐induced ACSL1 upregulation can be mitigated either by ACSL1 knockdown or metformin treatment, restoring the metabolic balance and promoting cardiomyocyte proliferation through modulation of the PKB/FOXO1 signaling pathway. Created with BioRender.com. ACSL1 indicates acyl‐CoA synthetase long‐chain family member 1; ADP, adenosine diphosphate; ATP, adenosine triphosphate; CoA, coenzyme A; FAT, fatty acid translocase; FOXO1, forkhead box O1; GLUT4, glucose transporter type 4; HK, hexokinase; IRI, ischemia–reperfusion injury; LCFAs, long‐chain fatty acids; MI, myocardial infarction; PDH, pyruvate dehydrogenase; PKB, protein kinase B; PFK, phosphofructokinase; and TG, triglycerides. Schematic illustration of ACSL4 and ACSL6 functions in neurons following IS. Following IS, ACSL4 expression is markedly upregulated and serves as a key mediator of ferroptosis by promoting lipid peroxidation in neuronal membranes. ACSL4 further increases susceptibility to ferroptosis by inhibiting GPX4. Dysregulated ACSL4 activity can impair mitochondrial membrane integrity through disrupted cardiolipin remodeling, leading to elevated ROS and defective mitochondrial clearance. Ischemia‐induced upregulation of ACSL4 is driven by transcriptional activation via Sp1 and posttranslational modification by PKCβII, and its activity can be attenuated by PPARγ, ferrostatin‐1, and liproxstatin‐1. In contrast, ACSL6 facilitates the incorporation of CoA into DHA, which is essential for DHA retention and metabolism. ACSL6 deficiency impairs DHA metabolism and reduces the synthesis of neuroprotective phospholipids, including NPD1 and other specialized proresolving mediators, thereby compromising neuronal survival and brain function after ischemic stroke. Created with BioRender.com. AA indicates arachidonic acid; ACSL4, acyl‐CoA synthetase long‐chain family member 4; ACSL6, acyl‐CoA synthetase long‐chain family member 6; AdA, adrenic acid; CoA, coenzyme A; DHA, docosahexaenoic acid; GPX4, glutathione peroxidase 4; IRI, ischemia–reperfusion injury; LPCAT3, lysophosphatidylcholine acyltransferase 3; MANF, mesencephalic astrocyte‐derived neurotrophic factor; NPD1, neuroprotectin D1; OOH, hydroperoxide; PE, phosphatidylethanolamine; PKCβII, protein kinase C‐beta II; PPARγ, peroxisome proliferator‐activated receptor gamma; ROS, reactive oxygen species; SPMs, specialized proresolving mediators; Sp1, specificity protein 1; TREM2, triggering receptor expressed on myeloid cells 2; 15‐LOX, 15‐lipoxygenase. Schematic illustration of ACSL isoform‐mediated and inflammatory crosstalk linking MI and IS. MI and IS are interconnected through shared metabolic dysregulation and inflammatory pathways mediated by distinct ACSL isoforms across immune, cardiac, and neural cells. In circulating monocytes, hyperlipidemia and ischemic stress induce ACSL1 expression, promoting the LPC/LPA axis, neutrophil activation, and NET formation, thereby amplifying thromboinflammation and contributing to both MI and secondary IS. In cardiomyocytes, ischemia‐associated lipid accumulation increases LCFA availability. ACSL4 converts LCFAs into peroxidizable lipid species, driving lipid peroxidation and ferroptotic cell death, which is modulated by mitochondrial quality control pathways and can be attenuated by genetic or pharmacological inhibition of ACSL4. Similarly, in neuronal cells following IS, elevated ACSL4 activity enhances LCFA incorporation into oxidizable phospholipids, promoting lipid peroxidation and ferroptosis, thereby exacerbating neuronal injury. Circulating and locally released miR‐22‐3p after MI further modulates ACSL4 expression and ferroptosis susceptibility across cardiac and neural compartments. Collectively, this schematic highlights ACSL1‐dependent immunometabolic activation and ACSL4‐mediated ferroptosis as convergent mechanisms linking MI and IS. Created with BioRender.com. ACSL indicates acyl‐CoA synthetase long‐chain family member; CitH3, citrullinated histone H3; CoA, coenzyme A; IS, ischemic stroke; LCFA, long‐chain fatty acid; LCFA‐OOH, long‐chain fatty acid hydroperoxide; LPA, lysophosphatidic acid; LPC, lysophosphatidylcholine; MI, myocardial infarction; miR‐22‐3p, microRNA‐22‐3p; MPO, myeloperoxidase; and NET, neutrophil extracellular trap. As lipid metabolism gains increasing attention in cardiovascular and neurodegenerative diseases, understanding the complex functions of the ACSL family could provide novel insights into the mechanisms of acute ischemic events and aid in identifying potential therapeutic targets. SEARCH STRATEGY AND SELECTION CRITERIA A systematic literature search was conducted in PubMed, Web of Science, Embase, and Scopus to identify relevant studies (clinical, translational, and preclinical) on the roles of the ACSL family in MI and IS. The search strategy combined controlled vocabulary (eg, MeSH terms) and free‐text keywords (eg, “ACSL1,” “ACSL4,” “acute myocardial infarction,” “cerebral ischemia,” “ferroptosis,” and “fatty acid metabolism”) using Boolean operators. The search was performed from database inception to December 2025. Reference lists of key articles were manually screened to capture additional relevant studies. Eligible studies included original research articles published in peer‐reviewed English‐language journals that reported data on the expression, regulation, or function of ACSL isoforms within the context of MI, IS, or related ischemia/reperfusion models. Studies involving human subjects, in vivo animal models, or relevant in vitro/ex vivo assessments were considered. Exclusion criteria encompassed review articles, editorials, conference abstracts without full data, case reports with limited sample size (unless providing unique mechanistic insight), and studies lacking sufficient methodological details for critical appraisal. To ensure translational breadth, this review synthesized findings from (1) clinical and epidemiological studies, (2) translational studies using human biospecimens, and (3) preclinical studies in animal models and cellular systems. METABOLIC STRESS RESPONSES IN MI Energy Metabolism in a Healthy Heart A healthy human heart can use a variety of energy‐containing substrates, including fats, carbohydrates, and ketone bodies, for respiration. Research indicates that anaerobic glucose metabolism serves as the primary energy source in embryonic cardiomyocytes. As these cells mature, they undergo a metabolic shift from anaerobic glucose metabolism to an increased reliance on FA β‐oxidation. 16 This metabolic shift persists into adulthood, where the mature heart derives ∼70% of its energy from FA β‐oxidation, with the remaining contribution coming from glucose, lactate, ketone bodies, and amino acids. 5 In adult mammals, triglycerides and long‐chain FAs (LCFAs) are critical energy reservoirs in the heart, with LCFAs serving as the preferred substrate for mitochondrial oxidation under aerobic conditions. During oxygen and nutrient deprivation, reliance on LCFA metabolism becomes even more pronounced, providing essential support for energy production and cellular functions. 17 Upon uptake by the cardiomyocytes, LCFAs are transported into the mitochondria, where they are converted into acyl‐CoA esters via the enzymatic action of ACSLs. 9 It is worth noting that the mitochondria constitute ∼25% and 35% of the cardiomyocyte volume in adult mammals and are essential for adenosine triphosphate (ATP) production through oxidative phosphorylation. 18 Subsequently, these acyl‐CoA esters are degraded into acetyl‐CoA through the β‐oxidation pathway. 19 This process can further activate FAs for subsequent metabolic processes to produce energy. Under normal physiological conditions, cardiac energy metabolism maintains a homeostatic equilibrium. However, in disease states such as MI, disruptions in substrate availability and use can significantly alter this balance, 20 where ischemia and subsequent reperfusion impose substantial metabolic stress on cardiomyocytes. Metabolic Stress Response During Ischemia in MI MI, depending on its severity and duration, triggers distinct metabolic adaptations to manage reduced oxygen availability. These responses vary across acute/sudden ischemia, mild‐to‐moderate chronic ischemia, and prolonged hypoxia. 4 , 21 During an acute ischemic episode, the abrupt loss of blood flow rapidly suppresses oxidative metabolism of both LCFAs and glucose. To maintain ATP production under these conditions, the heart upregulates anaerobic glycolysis, thereby conserving the limited oxygen supply. In ischemic rat models, substrate use in cardiomyocytes shifts from FAO toward glycolysis. 22 Clinical studies further support this metabolic reprogramming, indicating increased plasma FAs in patients with MI compared with the control group. 18 , 23 In addition, FAO is compromised during ischemic conditions in rats, leading to internalization of FAT (FA translocase/CD36) from the sarcolemma, thereby reducing FA uptake. This adaptive response helps prevent excessive lipid accumulation within the cardiomyocytes and mitigates lipotoxic injury. 22 In contrast to acute ischemic attacks, FAO remains the predominant contributor to residual oxidative metabolism during mild‐to‐moderate ischemia, despite increased glycolytic activity. 24 This occurs because elevated plasma FA levels following mild‐to‐moderate MI enhance their uptake into cardiomyocytes, sustaining mitochondrial FAO. By contrast, prolonged exposure to hypoxia/ischemia has a devastating impact on the heart. When FAO fails to match the increased supply and uptake of FAs, myocardial triglyceride accumulate, triggering lipotoxicity, oxidative stress, calcium dyshomeostasis, and cardiomyocyte injury, ultimately contributing to cardiac dysfunction. 25 As shown in mouse models of heart failure, excessive reliance on FAO also suppresses glucose use and oxidation, a key component of aerobic metabolism in cardiomyocytes. 26 Consequently, anaerobic glycolysis becomes the dominant energy source. However, impaired glycolysis in the absence of adequate glucose availability results in the accumulation of harmful lactate and protons, 27 causing intracellular acidosis and electrolyte imbalance, which further exacerbates cardiac dysfunction. Metabolic Stress Response During MI Reperfusion The reperfusion phase, rather than the ischemic phase, is broadly recognized as the primary driver of irreversible pathophysiological damage in cardiomyocytes. This is largely attributed to the burst of oxygen free radicals during reperfusion, which trigger oxidative stress and apoptosis. 28 In isolated perfused rodent hearts, short‐term ischemia (≤20 minutes) does not typically cause immediate cell death, as oxygen consumption gradually recovers during early reperfusion. In contrast, a prolonged ischemic episode (≥25 minutes) predisposes cells to death despite the rapid restoration of oxygen and nutrients in early reperfusion. Specifically, prolonged ischemia suppresses anaerobic glycolysis and glucose oxidation while elevating FAO. 22 Upon reperfusion, the sudden oxygen influx drives excessive FAO and overactivation of 5′ AMP‐activated protein kinase in response to abrupt energy demands. 29 Although a gradual metabolic recovery, as seen after brief ischemia, can be cardioprotective, a rapid surge in FAO during severe reperfusion diminishes myocardial efficiency. This is further aggravated by suppression of glucose oxidation via the Randle cycle, leading to a mismatch between glycolysis and glucose oxidation. 30 The resulting imbalance promotes intracellular acidosis and ion dyshomeostasis, compounding myocardial injury. From a therapeutic perspective, strategies that promote glucose oxidation while suppressing FAO could mitigate the metabolic stress, reduce toxic byproducts, and improve myocardial efficiency and recovery following ischemia–reperfusion injury (IRI). 26 In summary, the adult heart depends predominantly on FAO to meet its high‐energy demands, rendering the regulation of FA metabolism essential for the maintenance of cardiomyocyte homeostasis. Myocardial IRI disrupts this balance, driving profound alterations in energy metabolism. This review has outlined critical metabolic shifts that occur during ischemia and reperfusion, underscoring the importance of understanding these processes to guide the development of therapies that can restore the metabolic balance and improve patient outcomes. However, the interplay between energy transfer and cardioprotection remains incompletely defined, warranting further investigation. Within this context, the ACSL family plays an indispensable role by activating LCFAs for subsequent β‐oxidation, lipid synthesis, or membrane incorporation. Emerging evidence suggests that individual ACSL isoforms contribute uniquely to cardiac energy metabolism and are differentially regulated during ischemia and reperfusion. 9 , 19 Therefore, elucidating how specific ACSLs can direct the fate of FAs under ischemic stress holds significant promise for uncovering novel cardioprotective mechanisms and therapeutic opportunities. THE ROLES OF ACSLs IN MI The Roles of ACSL1 in Cardiac Health A primary function of ACSLs is to catalyze the conversion of LCFAs into long‐chain fatty acyl‐CoAs, a crucial step for ATP synthesis. Beyond their role in energy generation, ACSLs contribute to the biosynthesis of phospholipids, cholesterol esters, and triglycerides. Five ACSLs have been identified in rat and mouse hearts, as well as in isolated adult rat cardiomyocytes. Among these isoforms, ACSL1 accounts for >90% of ACSL activity across all isoforms, followed by ACSL5, ACSL4, ACSL3, and ACSL6. 31 Given its predominant role, we reviewed recent literature on ACSL1's primary functions, particularly in the context of MI. Using isoform‐specific antibodies, ACSL1 is predominantly localized to the mitochondrial membrane, endoplasmic reticulum, and cytoplasm. 32 During murine heart development, ACSL1 emerges as the dominant isoform responsible for the activation of LCFAs for myocardial oxidation. 33 As a pivotal rate‐limiting enzyme in lipid metabolism, ACSL1 plays a critical role in cardiac energy homeostasis, influencing both the structural integrity and functional capacity of the heart. 34 Moreover, ACSL1 expression modulates intracellular FA distribution and concentrations, linking it to the pathogenesis of metabolic disorders such as hepatic steatosis, atherosclerosis, and diabetes. 15 , 35 Given ACSL1's central role in lipid metabolism, ACSL1 has been identified as a potential biomarker for cardiovascular disease through genomic analysis. 36 Studies in mouse models with cardiac‐specific overexpression of ACSL1 indicate that disruption of the delicate balance between FA uptake and oxidation induces cardiac dysfunction. 37 This metabolic flexibility, coordinating FA activation, oxidation, and substrate selection, is particularly critical under hypoxic stress, when limited oxygen availability challenges cardiac energy homeostasis. Accordingly, dysregulated ACSL1 activity aggravates metabolic imbalance and impairs cardiac function, especially in MI, when the precise regulation of substrate use is essential to meet shifted energy demands. The Roles of ACSL1 in MI Development Patients with MI commonly exhibit high levels of fasting blood glucose, total cholesterol, and triglycerides, all of which are established risk factors for atherosclerosis. 38 Although the precise role of ACSL1 in MI remains uncertain, its central involvement in lipid and glucose metabolism suggests a potential contribution to MI development. Indeed, ACSL1 gene and mRNA expression are significantly upregulated in the peripheral blood of patients with MI, along with upregulated ACSL protein expression in the heart of mouse MI models. 39 , 40 In mice, ACSL1 directs acyl‐CoAs toward β‐oxidation, thereby decreasing glucose use and exacerbating diabetes‐related atherosclerosis, a major underlying cause of MI. 36 Human studies further support this connection, identifying 3 single‐nucleotide variants in ACSL1 that are correlated with fasting glucose levels, diabetes, and subclinical atherosclerosis. For instance, single‐nucleotide variant rs4862423 has been linked to subclinical atherosclerosis and localizes to DNase I hypersensitive sites with high accessibility in the human heart. 41 In mouse cardiomyocytes, ACSL1 deletion drives a metabolic switch from FAO to glycolysis, promoting ventricular hypertrophy that mirrors the pathological changes observed in human heart failure. 10 , 42 Beyond metabolism, ACSL1 also contributes to inflammatory signaling: pathogen‐associated factors such as lipopolysaccharide and TNF‐α (tumor necrosis factor‐α) robustly induce ACSL1 expression in blood, 43 , 44 and elevated ACSL1 levels have been reported in fatal sepsis. 44 Given the critical role of inflammation in MI pathogenesis, these findings position ACSL1 as a key regulator at the intersection of metabolic and inflammatory pathways. Collectively, evidence suggests that elevated ACSL1 expression is associated with increased MI risk and highlights its potential utility as a molecular marker for early diagnosis. ACSL1 Regulation Post MI One of the major hallmarks following MI is cardiac hypertrophy. To compensate for the loss of viable myocardium and the increased workload placed on surviving cardiomyocytes, the heart undergoes adaptive (compensatory) hypertrophy, wherein the remaining myocytes enlarge to preserve cardiac output. Later in this review, we discuss how ACSL1 regulates cardiac hypertrophy and its potential role in the compensatory remodeling process (Figure 1). Overexpression of ACSL1 in mouse cardiac tissue has been shown to promote triglyceride accumulation within cardiomyocytes. This lipid buildup is strongly associated with the development of cardiac hypertrophy, which can subsequently progress to left ventricular dysfunction and premature mortality. 37 The detrimental role of ACSL1 after MI is further supported by in vivo studies indicating that knockdown of ACSL1 reinstates cardiac function and promotes myocardial regeneration in adult mice following MI. 40 This recovery appears to be mediated by the PKB (protein kinase B)/FOXO1 (forkhead box O1) signaling pathway, which facilitates cardiomyocyte re‐entry into the proliferative state. 40 Moreover, mice with whole‐body and cardiac‐specific ACSL1 deficiency exhibited a significant reduction in FAO and myocardial lipid content, alongside a compensatory increase in glucose and pyruvate oxidation. These metabolic alterations ultimately led to cardiac hypertrophy and diastolic dysfunction. 10 , 44 Although the majority of the studies have reported that ACSL1 plays a detrimental role in MI, a few have suggested potential cardioprotective effects of ACSL1 against MI. For instance, overexpression of cardiac ACSL1 in mice has been shown to mitigate the adverse effects of altered lipid profiles in hypertrophic hearts by enhancing ceramide production. Importantly, these beneficial effects are only observed when ACSL1 is overexpressed at low levels in a cardiac‐specific manner. This targeted approach helps maintain acyl‐CoA content while redirecting the metabolic fate of acyl intermediates away from lipotoxic ceramide species in the pathologically stressed heart, such as cardiac hypertrophy and heart failure induced by transverse aortic constriction. 45 , 46 Another example of ACSL1's potential cardioprotective role is highlighted in a study conducted by Wright et al. 47 They showed that the antiapoptotic molecule MCL‐1 (myeloid cell leukemia‐1) interacts with ACSL1 through a shared B‐cell lymphoma 2 homology 3‐like domain. This interaction facilitates FAO in both cells and mouse tissues under normal physiological conditions. However, under cellular stress, such as ischemia, the interaction between MCL‐1 and ACSL1 can be disrupted, leading to impaired LCFA oxidation. 47 ACSL1 also plays important roles in other cardiac cell populations that participate in post‐MI remodeling. The heart is a multicellular organ, and accumulating evidence indicates that ACSL1 is functionally relevant in several nonmyocyte compartments. In cardiac fibroblasts, ACSL1 forms part of the FAO machinery in the quiescent state but becomes downregulated during fibrotic remodeling, contributing to metabolic reprogramming that promotes activation of myofibroblasts. 48 Additionally, ACSL1 is highly expressed in macrophages, where hyperglycemia, toll‐like receptor ligands, and other inflammatory or metabolic cues markedly induce its expression, resulting in elevated ACSL1 mRNA and protein levels in diabetic and proatherogenic settings. 49 , 50 Correspondingly, myeloid‐selective ACSL1 deletion prevents diabetes‐accelerated atherosclerosis. 49 Collectively, ACSL1 is the most ubiquitously expressed member of the ACSL family in cardiac tissue, with elevated expression observed in both peripheral blood and cardiomyocytes of patients following MI. It plays a critical role in the pathogenesis and progression of MI, and accumulating evidence suggests that ACSL1 can serve as a promising therapeutic target. Nevertheless, any regulatory strategies aimed at enhancing cardioprotection in the context of IRI must be carefully evaluated for their impact on overall energy homeostasis, as well as the risk of cardiotoxicity arising from the accumulation of harmful lipotoxic FA intermediates. Given its dual role in both protective and pathological processes, ACSL1 functions as a double‐edged sword in cardiac metabolism. METABOLIC STRESS RESPONSE IN IS Unlike the heart, which predominantly relies on LCFAs as its primary energy source, the brain primarily uses glucose as its main fuel in both adults and developing individuals. This metabolic preference is largely due to the limited ability of FAs to cross the blood–brain barrier, whereas glucose is readily transported into the brain via GLUTs (glucose transporters; GLUT1 and GLUT3). 51 During normal physiological conditions, >95% of the brain's ATP is produced through mitochondrial oxidative phosphorylation of glucose. However, during metabolic challenges such as prolonged fasting or starvation, the limited reserve of intracellular glucose and glycogen in the brain can sustain ATP production for only a few minutes. Therefore, the brain adapts by using alternative substrates, primarily ketone bodies (derived from hepatic FA metabolism) and lactate, to compensate for energy homeostasis. 52 Even though lipid metabolism is not the primary energy source for the brain, lipids and their intermediates are crucial for maintaining the brain's structural integrity and functionality. Remarkably, the human brain has the second‐highest lipid content among all tissues, exceeded only by adipose tissue. 53 It predominantly uses acylated lipids for phospholipid synthesis and exhibits a unique FA profile enriched with omega‐3 or omega‐6 LCFAs, such as arachidonic acid, docosahexaenoic acid (DHA), and eicosapentaenoic acid. These LCFAs are not only structural components of neuronal membranes but also play fundamental roles in neurodevelopment, synaptic function, and cell signaling. 54 At the cellular level, neurons are the principal functional cells of the brain, which express various molecular components involved in lipid catabolism, such as ACSLs, carnitine palmitoyltransferases, and β‐oxidation enzymes (eg, acyl‐CoA dehydrogenases, enoyl‐CoA hydratase, 3‐hydroxyacyl‐CoA dehydrogenase, and 3‐ketoacyl‐CoA thiolase), highlighting the relevance of lipid use to neuronal activity. 55 In addition, emerging evidence highlights the metabolic crosstalk between neurons and brain‐resident immune cells (eg. astrocytes). Although astrocytes are well known for their role in glycolytic lactate production, they also exhibit considerable mitochondrial FAO capacity. 56 Studies suggest that astrocytic mitochondrial FAO can supply up to 20% of the brain's energy needs, particularly during periods of heightened metabolic demand, such as fasting, high‐fat diet consumption, or intense neuronal activation. 57 The astrocytic lipid catabolism not only generates ketones as alternative energy substrates but also plays a pivotal role in modulating neuronal lipid homeostasis, with clear relevance to human brain physiology. 58 These lipid‐driven metabolic adaptations are particularly relevant under pathological conditions, such as cerebral ischemia, where glucose and oxygen availability are severely compromised. The relevance is further underscored by clinical observations of elevated circulating free FAs and triglycerides in patients with stroke. 59 , 60 Understanding how brain cells coordinate their responses through lipid metabolism is critical for unveiling novel neuroprotective strategies and therapeutic targets. Hence, lipid signaling has emerged as a key mediator of the brain's response to ischemic injury. Ischemia and subsequent reperfusion activate a broad range of lipid metabolism pathways, resulting in the production of bioactive lipids and second messengers that can exert either neuroprotective or deleterious effects. Recent studies in mouse and rat stroke models have mapped the spatial and temporal distribution of phospholipids following stroke, documenting region‐specific changes in lipid composition across the ischemic core, penumbra, and adjacent healthy tissue. 61 , 62 These findings reveal the complexity of lipid metabolism in ischemic pathophysiology and point to the potential of lipidomic profiling for identifying novel biomarkers and therapeutic targets aimed at limiting infarct expansion and improving recovery. THE ROLES OF ACSLs IN IS The Roles of ACSLs in Brain Activity As key regulators of FA metabolism, emerging evidence indicates that ACSLs not only govern metabolic reprogramming but also influence neuroinflammation, mitochondrial dynamics, and neuronal viability after ischemia. 63 These insights set the stage for a deeper examination into the specific functions and regulatory mechanisms of individual ACSL isoforms in the context of IS. The expression of ACSLs in the brain varies by the developmental stage, with ACSL3, ACSL4, and ACSL6 being predominantly expressed and exhibiting distinct temporal and spatial patterns that reflect their unique physiological roles (TableTable1). Specifically, ACSL3 is primarily involved in early rat brain development. Its expression peaks around postnatal day 15, followed by a marked decline to ∼10% of its maximal level in the adult brain. 64 This transient surge suggests a developmental role, potentially supporting the lipid demands required for rapid neuronal growth and differentiation during early postnatal stages. Conversely, ACSL6 is abundantly expressed in the adult mouse brain, with particularly strong enrichment in the cerebellum and hippocampus, regions critical for motor coordination and spatial memory, respectively. 11 , 65 ACSL6 demonstrates substrate specificity for DHA and is expressed in both neurons and astrocytes. However, only the neuronal isoform of ACSL6 efficiently facilitates DHA enrichment in membrane phospholipids, whereas the astrocytic variant of ACSL6 exhibits low affinity for DHA. 11 Functional studies in ACSL6‐deficient mice revealed hyperlocomotion, impaired working spatial memory, and upregulation of cholesterol biosynthesis genes, highlighting its essential role in maintaining neuronal lipid homeostasis throughout adulthood. 11 Clinically, variants in the ACSL6 gene have been associated with astrocytoma, suggesting a potential contribution of ACSL6 dysregulation to brain tumorigenesis. 66 In addition to ACSL3 and ACSL6, ACSL4 is another isoform predominantly expressed in the adult brain, with particularly high levels in the hippocampus and moderate expression in regions such as the cerebellum. 67 ACSL4 exhibits strong substrate specificity for arachidonic acid and plays pivotal roles in neuronal differentiation, synaptic spine formation, and the establishment of functional neural circuits. 67 Importantly, mutations in the ACSL4 gene have been associated with nonsyndromic X‐linked intellectual disability, underscoring its indispensable function in neurodevelopment and cognition. 68 Because most research on ACSL regulation in ischemic brain injury has focused on ACSL4 and ACSL6, we discuss their regulation and functional significance under ischemic conditions in the following subsections. The Roles of ACSLs in IS Development Among the ACSLs, ACSL4 has garnered significant attention under the scope of cerebral ischemia because of its marked upregulation in experimental models of IS, especially those involving IRI. Elevated expression of ACSL4 has been shown to exacerbate neuronal damage, suggesting that ACSL4 is actually detrimental during cerebral ischemia in both cellular and animal models. The contribution of ACSL4 to ischemic brain injury is primarily attributed to its role in ferroptosis, a regulated form of iron‐dependent lipid peroxidation‐induced cell death that amplifies tissue injury during the reperfusion phase. 69 , 70 Beyond its involvement in ferroptosis, studies also suggest that ACSL4 can increase the composition of mitochondrial phospholipids, especially cardiolipin, a mitochondria‐specific phospholipid critical for maintaining electron transport chain activity and mitophagy. This ACSL4‐mediated lipid remodeling can further compromise mitochondrial membrane integrity, disrupt oxidative phosphorylation, and inhibit mitophagy during/after cerebral ischemia, thereby compounding cellular dysfunction and injury. 70 , 71 , 72 , 73 ACSL4 Regulation Post IS Following IS, ACSL4 is a key mediator of neuronal injury, primarily driving ferroptosis, an iron‐dependent form of programmed cell death. ACSL4 is a key enzymatic regulator of ferroptosis, selectively activating polyunsaturated FAs, particularly arachidonic acid and adrenic acid. These FAs are converted into their CoA derivatives and incorporated into membrane phospholipids, primarily phosphatidylethanolamine, via LPCAT3 (lysophosphatidylcholine acyltransferase 3). 13 Once incorporated, these polyunsaturated FA‐phosphatidylethanolamine species serve as substrates for enzymatic oxidation by lipoxygenases (eg, 15‐LOX [15‐lipoxygenase]), initiating lipid peroxidation that culminates in ferroptotic cell death. 74 This process is further amplified by iron‐dependent Fenton reactions, which catalyze reactive oxygen species production and accelerate lipid peroxidation. 75 Following ischemic injury, ACSL4 expression is significantly upregulated in cellular and rodent models of cerebral ischemia/reperfusion, driven by both transcriptional mechanisms, via Sp1 (specificity protein 1) activation, and posttranslational modifications, such as PKCβII (protein kinase C‐beta II)‐mediated phosphorylation. 76 , 77 These regulatory events increase ACSL4 activity, thereby increasing neuronal susceptibility to ferroptosis during ischemia/reperfusion events. From a therapeutic standpoint, pharmacological inhibitors of ferroptosis, such as liproxstatin‐1 and ferrostatin‐1, have been shown to disrupt ACSL4‐mediated lipid peroxidation, offering neuroprotection and functional recovery in preclinical stroke models. 78 , 79 Similarly, in a mouse model of transient middle cerebral artery occlusion, the PPARγ (peroxisome proliferator‐activated receptor gamma) agonist rosiglitazone, downregulates ACSL4 expression while limiting ferroptotic injury, further supporting ACSL4's therapeutic potential against cerebral ischemia. 79 Moreover, ACSL4 inhibition has been shown to preserve GPX4 (glutathione peroxidase 4) expression, a key antioxidant enzyme that neutralizes lipid hydroperoxides and thereby protects against ferroptosis post‐ischemia, potentially restoring the cell's antioxidant capacity and reducing neuronal death. 70 , 79 Collectively, ACSL4 emerges as a critical determinant of neuronal fate after IS through its regulation of ferroptotic processes. ACSL6 Regulation Post IS Contrary to the proferroptotic role of ACSL4, ACSL6 serves a neuroprotective function in the brain by facilitating the activation and incorporation of DHA into neuronal membrane phospholipids. DHA has been extensively studied for its therapeutic potential following cerebral ischemia, and its integration into neuronal membranes enhances membrane fluidity, stability, and integrity, thereby supporting synaptic function and cellular resilience under ischemic stress. 55 ACSL6 catalyzes the formation of DHA‐CoA, a crucial intermediate required for the intracellular retention and metabolism of DHA. Deficiency of ACSL6 in the mouse brain impairs DHA use and diminishes the production of DHA‐enriched neuroprotective phospholipids, highlighting its importance in maintaining neuronal homeostasis and stress resistance. 11 Beyond ACSL6's role in DHA activation, it also contributes to the biosynthesis of proresolving mediators, such as resolvins and protectins, which are critical for resolving neuroinflammation and promoting tissue repair after ischemic injury. 80 In summary, both ACSL4 and ACSL6 are prominently expressed in the adult brain, with ACSL4 showing marked upregulation in stroke models. Although ACSL4 promotes ferroptosis under ischemic conditions, ACSL6 appears to exert opposing effects through DHA‐driven antioxidant and anti‐inflammatory pathways (Figure 2). Despite the recognized neuroprotective role of ACSL6, its regulation and therapeutic relevance in IS remain poorly understood. In light of the key role of lipid metabolism in the neural and cardiac tissues, a deeper understanding of how ACSL isoforms coordinate metabolic responses across the brain–heart axis is expected to offer valuable insights into their systemic impact during ischemic injury. METABOLIC INTEGRATION IN THE BRAIN–HEART INTERACTION Crosstalk of Metabolic Pathways Between the Brain and Heart Disruptions in lipid and glucose metabolism, neuroendocrine signaling, and inflammation commonly occur following cerebral ischemia, triggering complex bidirectional interactions between the brain and heart. The concept of the heart–brain axis was first proposed in the 19th and 20th centuries and later formalized under the discipline of neurocardiology. The heart–brain axis describes the dynamic reciprocal communication between the cardiovascular and central nervous systems. 81 This concept has since evolved into a multidisciplinary framework encompassing cardiology, neurology, and immunology. Cardiac dysfunction, including reduced output or ischemic damage, has been shown to impair the cerebral perfusion, leading to structural brain alterations, such as white matter degradation and reduced brain volume. 82 Conversely, cerebral ischemia, including that triggered by cardiac arrest, can induce severe cardiac arrhythmias and autonomic instability. 83 Therefore, disruptions in this bidirectional communication can exacerbate both cardiac and neurological outcomes following ischemic events. Brain–Heart Metabolic Interaction Under Ischemia Both IS and MI share common risk factors such as hypertension, diabetes, and dyslipidemia, which contribute to systemic inflammation and neuroendocrine imbalance. 84 During ischemia, elevated reactive oxygen species and activation of the hypothalamic paraventricular nucleus enhance sympathetic output and inflammatory signaling. Experimental studies in mice and rats have shown that stroke‐induced paraventricular nucleus activation triggers cardiac arrhythmias through N‐methyl‐D‐aspartate receptor‐mediated excitation, whereas suppression of paraventricular nucleus activity improves cardiac recovery after MI. 85 , 86 The sympathetic nervous system serves as a key mediator of this interaction. Pressure overload sensed by the cardiac afferent nerves stimulates sympathetic efferents to release ATP, which activates P2X7 receptors and the NLRP3 (NOD‐, LRR‐ and pyrin domain‐containing protein 3) inflammasome, thereby promoting inflammation and hypertrophy in cardiac tissue. 87 At the metabolic level, ischemia increases circulating free FAs and disturbs lipid and glucose homeostasis in both the brain and heart. Dysregulation of key enzymes such as ACSLs and carnitine palmitoyltransferases further contributes to mitochondrial dysfunction and energy imbalance. 88 , 89 Collectively, these processes form a vicious cycle that integrates neural, endocrine, and metabolic injury across the brain–heart axis. In the following sections, we explore the roles of the ACSL family in modulating this axis under ischemic stress (Figure 3). THE ROLE OF THE ACSLs IN BRAIN‐HEART INTERACTION Isoform‐Specific Roles of ACSLs in the Brain–Heart Metabolic Pathways Within the metabolic network linking the brain and heart, ACSLs act as central gatekeepers that convert LCFAs into acyl‐CoAs, thereby shaping organ‐specific energy use, membrane remodeling, and lipid‐derived inflammatory signaling. 9 Importantly, individual ACSLs exhibit distinct tissue distributions and functional specializations, enabling coordinated yet divergent metabolic responses across the brain–heart axis. ACSL1 plays a dual role in this coordination. Under physiological conditions, it promotes β‐oxidation to support cardiac energy homeostasis; however, during systemic metabolic stress (eg, sepsis or high‐fat diet) in mice, its upregulation in macrophages can potentiate proinflammatory signaling, thereby compromising cerebrovascular integrity and exacerbating neuroinflammation. 90 , 91 In contrast, ACSL4 is highly enriched in neural tissue, where it drives lipid peroxidation and ferroptosis, a process that amplifies oxidative injury and has been implicated in the propagation of ischemic damage from the brain to the heart. 73 , 75 Meanwhile, ACSL6 supports neuroprotection by incorporating DHA into neuronal membranes and promoting the synthesis of anti‐inflammatory lipid mediators, including resolvins, neuroprotectin D1, and maresins. These processes enhance neuronal resilience and indirectly help stabilize autonomic function, offering potential cardioprotection. Furthermore, ACSL6‐driven production of DHA‐derived mediators, such as resolvins and neuroprotection D1, facilitates immune cell phagocytosis and resolves inflammation after stroke, reinforcing both neuro‐ and cardioprotection. 11 , 80 Other ACSL isoforms also play roles in brain–heart metabolic coordination. For example, ACSL3 has been implicated in regulating embryonic development, particularly in early neurocardiac programming. 14 , 33 Although ACSL5 is minimally expressed in healthy brain tissue, it is markedly upregulated in malignant gliomas. Notably, patients with malignant gliomas exhibit a significantly higher risk of cardiovascular events 92 , suggesting a potential role for ACSL5 in mediating heart–brain metabolic crosstalk. Apart from its role in lipid metabolism, ACSL5 is also involved in glucose regulation, affecting ischemic vulnerability. Deletion of ACSL5 in mice enhances insulin sensitivity, reduces adiposity, and increases energy expenditure 93 , demonstrating that ACSL5 may negatively affect metabolic homeostasis. These systemic metabolic benefits from ACSL5 inhibition may enhance resilience to ischemic injury in both the heart and brain, particularly in the context of metabolic syndrome. ACSL‐Mediated Mechanisms Linking MI and IS Although MI and IS occur in different organs, both initiate abrupt metabolic failures followed by inflammation, ferroptosis, and oxidative stress during reperfusion. ACSL enzymes critically shape these shared and organ‐specific injury pathways. The adult heart relies heavily on FAO for ATP generation, making ACSL1‐mediated long‐chain acyl‐CoA formation essential for sustaining contractile function post‐MI. In contrast, the brain has limited capacity for mitochondrial β‐oxidation; thus, ACSL‐dependent polyunsaturated FA activation in the central nervous system primarily influences membrane composition and ferroptotic vulnerability rather than oxidative metabolism. Against this metabolic divergence, distinct ACSLs emerge as key executors of ischemic injury, with ACSL1 predominantly driving immunometabolic and thromboinflammatory responses, and ACSL4 governing ferroptotic susceptibility across the brain–heart axis (Figure 3). ACSL1 exemplifies a convergent pathological regulator linking MI and IS. In patients with acute MI, individuals with hyperlipidemia, and high‐fat–treated cellular models, ACSL1 upregulation in monocytes reprograms lipid metabolism toward lysophosphatidylcholine and lysophosphatidic acid accumulation, thereby enhancing neutrophil extracellular trap (NET) formation and amplifying thromboinflammation. Accordingly, genetic or pharmacological inhibition of ACSL1 (eg, triacsin C) effectively suppresses these responses. 94 Notably, NET‐forming neutrophils are abundantly detected in peri‐infarct brain tissue from patients with IS and mouse models of transient middle cerebral artery occlusion, and elevated circulating NET biomarkers correlate with worse stroke outcomes, whereas NET inhibition reduces infarct size and improves neurological recovery. 95 Single‐cell transcriptomic analyses revealed that ACSL1 is relatively enriched in microglia, where its upregulation under neurodegenerative conditions (eg, Alzheimer's and Parkinson's disease) is associated with lipid droplet accumulation, sustained microglial activation, and neurotoxicity. 96 , 97 Together, these findings position ACSL1 as a central immunometabolic node that links MI and IS through lipid‐driven thromboinflammation and microglial dysfunction, underscoring its significant role in brain–heart crosstalk. ACSL4 represents another key isoform linking MI and IS through ferroptosis. Across rodent middle cerebral artery occlusion models, genetic or pharmacologic ACSL4 inhibition reduces infarct size and improves neurological outcomes. 79 Ferroptosis similarly contributes to cardiac ischemic injury, because ACSL4 expression is upregulated in cardiomyocyte hypoxia models and in mouse models of acute MI, whereas suppression of ACSL4‐dependent ferroptosis, via pharmacological agents, genetic modulation, or posttranslational regulation, attenuates myocardial injury and improves the cardiac function. 98 Notably, following MI in mice, cardiomyocytes release exosomes enriched in miR‐22‐3p into the circulation; uptake of these exosomes suppresses ACSL4 expression in recipient cells, 99 suggesting a potential protective heart‐to‐brain signaling axis during stroke. ACSLs and Their Lipid Products as Emerging Clinical Biomarkers Given the central roles of ACSLs and their lipid products in metabolic reprogramming and ferroptotic vulnerability across MI and IS, they are increasingly recognized as promising biomarkers of metabolic stress, inflammatory activation, and ischemic injury. In acute MI, circulating ACSL1 mRNA and protein levels are significantly elevated compared with healthy controls and contribute to diagnostic gene‐expression signatures. Increased ACSL1 expression correlates with adverse lipid‐related risk profiles, including the extent of coronary atherosclerosis, as well as markers of myocardial injury and inflammation. 39 , 94 , 100 , 101 Consistently, in patients with hyperlipidemia with acute MI, ACSL1 upregulation is associated with higher cholesterol levels, elevated cardiac troponin, and enhanced thromboinflammatory activity. In this setting, circulating lysophosphatidic and lysophosphatidic acid are markedly increased and constitute part of an ACSL1‐dependent monocyte lysophosphatidic acid/lysophosphatidic acid axis that exacerbates myocardial IRI and inflammation. 94 In IS, ACSL4 mRNA plasma levels are significantly higher in patients with acute IS than in healthy individuals and demonstrate good discriminative ability for acute IS diagnosis. Moreover, patients with moderate‐to‐severe acute IS exhibit higher ACSL4 mRNA levels than those with mild stroke, supporting the potential of ACSL4 as both a diagnostic marker and a therapeutic target. 102 In addition, elevated serum ACSL4 protein levels are associated with poorer motor recovery in patients with poststroke sequelae undergoing modified constraint‐induced movement therapy, highlighting its prognostic relevance during stroke rehabilitation. 103 Furthermore, circulating long‐chain acylcarnitines (C16–C18), lipid intermediates generated through ACSL activity, rise sharply at presentation of acute IS and predict poorer neurological outcomes, reflecting upstream accumulation of long‐chain acyl‐CoAs under mitochondrial stress. 104 Although current evidence supporting ACSLs as clinical biomarkers remains limited, particularly for isoforms other than ACSL1 and ACSL4, these findings underscore their translational relevance and warrant further systematic investigation in larger and well‐characterized patient cohorts. CAVEAT: THE DOUBLE‐EDGED ROLES OF ACSLs IN CARDIAC AND NEURAL PATHOPHYSIOLOGY The diverse functions of ACSLs are both isoform specific and context dependent. For instance, ACSL4 promotes ferroptosis and contributes to tissue damage under pathological conditions, yet it is also indispensable for the biosynthesis of cardiolipin, a key mitochondrial phospholipid. 34 Similarly, ACSL1 supports cardiac energy metabolism under physiological conditions, but its overexpression can lead to lipotoxicity. 46 , 105 These highly complicated and conflicting roles underscore the importance of developing tissue‐ and condition‐specific strategies when targeting ACSLs for therapeutic purposes. To conclude, ACSLs are emerging as critical regulators of the brain–heart axis, particularly in the setting of ischemic injury. By modulating lipid metabolism, mitochondrial energetics, ferroptosis, and inflammation, the ACSL family shapes the outcomes of ischemic damage in both the heart and brain. Their activity affects not only tissue survival and repair but also neurobehavioral recovery and systemic metabolic balance. Given their isoform‐ and context‐specific effects, ACSLs represent promising yet intricate therapeutic targets, warranting further translational research to enable precise and effective interventions for both cardiovascular and neurodegenerative disorders. POTENTIAL FOR CLINICAL TRANSLATION Pharmacological inhibition of ACSL1 with triacsin C has shown efficacy in reducing myocardial injury. 94 , 106 Likewise, ACSL4 has emerged as a key contributor to cerebral ischemia through its role in lipid peroxidation and ferroptosis. 78 Its upregulation in ischemic brain tissue not only reflects ongoing neuronal damage but also positions ACSL4 as a potential biomarker for stroke severity. Therefore, it represents a promising candidate for integration into predictive tools, such as machine learning‐based risk models, to enhance clinical assessment in patients with coexisting cardiovascular and cerebrovascular risk factors. 69 , 70 , 107 In addition, pharmacological intervention with baicalein, a natural flavonoid, exerts a dual‐modulatory effect on the GPX4/ACSL4/ACSL3 axis in preclinical models of cerebral ischemia–reperfusion, including rat middle cerebral artery occlusion/reperfusion and oxygen–glucose deprivation and reoxygenation‐treated primary neurons. Baicalein effectively inhibits ferroptosis by simultaneously suppressing ACSL4 and enhancing ACSL3 expression, thereby improving neuronal survival and supporting functional recovery after stroke. 108 Despite these advances, several key translational challenges remain. First, the isoform‐specific and context‐dependent functions of ACSLs pose a significant obstacle in the treatment of ischemic heart and brain injury. A single ACSL isoform can exert either protective or harmful effects depending on the tissue type, disease stage, and metabolic state. Second, the optimal therapeutic window and duration of intervention have not been defined yet, which is a critical issue given the dynamic and time‐sensitive nature of ischemic injury in both organs. Third, the development of isoform‐selective modulators with adequate tissue specificity remains a major hurdle. For cerebral ischemia, candidate compounds must be capable of crossing the blood–brain barrier, whereas precise myocardial targeting is essential to ensure therapeutic efficacy while minimizing systemic off‐target toxicity in cardiac applications. Advancing ACSL‐targeted strategies into the clinical practice will require further preclinical validation in disease‐relevant animal models, followed by well‐designed clinical trials to rigorously assess safety, efficacy, and dosing parameters. CONCLUSIONS ACSLs play indispensable roles in the intricate metabolic crosstalk between the brain and heart under both physiological and pathophysiological conditions. By regulating lipid metabolism, energy production, ferroptosis, inflammation, and redox balance, ACSLs emerge as central modulators of ischemic injury and repair. Isoform‐specific functions, such as the deleterious role of ACSL4 in ferroptosis, the neuroprotective effect of ACSL6 through DHA incorporation, and the context‐dependent impact of ACSL1 on energy homeostasis, highlight their therapeutic promise while also underscoring the challenges and complexity of selectively targeting these enzymes. To advance the field, future research should prioritize (1) elucidating the regulatory mechanisms of ACSL isoforms within distinct cellular and metabolic contexts, (2) defining precise therapeutic windows, and (3) developing highly selective modulators capable of crossing the blood–brain barrier or achieving targeted delivery to cardiac tissue. This review synthesizes current insights into the roles of ACSLs in ischemic conditions, with an emphasis on their dual relevance to both cardiac and cerebral health. Bridging fundamental molecular understanding with translational research is critical for advancing next‐generation ACSL‐targeted therapies. Ultimately, such approaches hold substantial promise to transform the diagnosis, treatment, and long‐term management of ischemic disorders, improving clinical outcomes and patient quality of life. Sources of Funding This work was supported by the following grants and awards: National Institutes of Health/National Institute of Neurological Disorders and Stroke 5R01NS126273–04 to Reggie Hui‐Chao Lee, American Heart Association 25TPA1475809 to Reggie Hui‐Chao Lee, American Heart Association 23TPA1069224 to Reggie Hui‐Chao Lee, and American Heart Association 24SCEFIA1255866 to Celeste Yin‐Chieh Wu. Disclosures The authors declare no conflicts of interest. This article was sent to Neel Singhal, MD, PhD, Associate Editor, for review by expert referees, editorial decision, and final disposition. For Sources of Funding and Disclosures, see page 13. Contributor Information Celeste Yin‐Chieh Wu, Email: celestewu@usf.edu. Reggie Hui‐Chao Lee, Email: reggielee@usf.edu. References